CN103494197A - Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food - Google Patents
Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food Download PDFInfo
- Publication number
- CN103494197A CN103494197A CN201310466624.8A CN201310466624A CN103494197A CN 103494197 A CN103494197 A CN 103494197A CN 201310466624 A CN201310466624 A CN 201310466624A CN 103494197 A CN103494197 A CN 103494197A
- Authority
- CN
- China
- Prior art keywords
- weight
- powder
- extract
- health
- immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 210000004369 blood Anatomy 0.000 title abstract description 39
- 239000008280 blood Substances 0.000 title abstract description 39
- 230000002708 enhancing effect Effects 0.000 title abstract description 10
- 235000013305 food Nutrition 0.000 title abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000003809 water extraction Methods 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 17
- 241000233866 Fungi Species 0.000 claims description 15
- 240000001307 Myosotis scorpioides Species 0.000 claims description 15
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 244000241838 Lycium barbarum Species 0.000 claims description 13
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 239000012059 conventional drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 235000006533 astragalus Nutrition 0.000 abstract description 7
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 abstract 2
- 240000002624 Mespilus germanica Species 0.000 abstract 2
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 2
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 2
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 2
- 238000009835 boiling Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 42
- 239000008103 glucose Substances 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 14
- 201000001421 hyperglycemia Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 241001061264 Astragalus Species 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000004233 talus Anatomy 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- 108010001483 Glycogen Synthase Proteins 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000330899 Hepialus Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001416980 Paecilomyces hepiali Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- -1 pulvis Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/08—Food product presented as a kit of parts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a health-care food with functions of enhancing the immunity and assisting to reduce the blood sugar and a preparation method of the food. The health-care food is prepared by mixing the following components in parts by weight: of extract powder and 5-15 parts of cordyceps sinensis zymophyte powder, wherein the extract powder is prepared from 5-13 parts of astragalus membranaceus, 1-10 parts of rhizoma polygonati, and 1-10 parts of medlar through water extraction and concentration. The preparation method comprises the following steps: mixing the astragalus membranaceus, the rhizoma polygonati and the medlar; adding water, immersing and boiling; concentrating an extracting solution to prepare the extract powder; mixing the extract powder with the cordyceps sinensis zymophyte powder to obtain an active component provided by the invention. The health-care food provided by the invention has the double functions of enhancing the immunity and assisting to reduce the blood sugar. After diabetes mellitus patients take the health-care food for a long time, the blood sugar is controlled effectively and the immunity of an organism can be improved; the capability of resisting other diseases, particularly diabetes mellitus complications, of the organism is enhanced.
Description
Technical field
The invention belongs to the technical field of health food, refer more particularly to a kind of health food with enhancing immunity and auxiliary hyperglycemic function and preparation method thereof.
Background technology
Diabetes are diseases of a kind of serious harm human health, and according to statistics, the incidence of disease of diabetes is 3%～5% in the world, and the whole world has diabetic more than 100,000,000, and the incidence of disease per capita more than 50 years old is 10%.In China, along with change and the aging population of expanding economy and people's dietary structure, diabetic's quantity increases sharply.According to statistics, the illness rate in the Chinese Adult more than 20 years old reaches 9.7%, and the patient approaches 100,000,000 people.China's prediabetes is converted into the probability of diabetes up to 10%, is the twice of world average.
Diabetes can cause many complication, because diabetes are that carbohydrate metabolism disturbance absolute due to insulin in body or that relative deficiency causes is main systemic disease, take drink more, many foods, diuresis, lose weight, blood sugar and glucose in urine increase as principal character, vascular lesion, ketosis, acid poisoning easily occur, and the health that the patient in these complication serious threats is life even.According to American Studies, show, suffer from the patient of diabetes more than 20 years and have 95% the high 2-4 of possibility calibration ordinary person that PVR, diabetes patient suffer from a heart complaint to occur doubly, the danger suffered stroke is high 5 times, and old-aged diabetic over half dies from angiocardiopathy.In addition, the diabetic also may Nephropathy, DPN, disease of digestive tract, mouth disease, impotence, skin and joint disease and arterial obliterans of lower extremity etc.
At present, OHA commonly used has side effect clinically, all can cause gastral bad should, some also causes measles, anaemia, leucocyte and thrombopenia, dizziness and weak etc.So develop a health food with enhancing immunity and auxiliary hyperglycemic effect, to coordinate drug therapy, reduction side effect when effectively controlling blood sugar and diabetic complication, raising immunity of organisms have caused people's attention.
Summary of the invention
The purpose of this invention is to provide a kind of the have immunity of enhancing and the bifunctional health food of auxiliary hyperglycemic and preparation method thereof, for the diabetic provides a effective control blood sugar, provide the health food of immunity, minimizing diabetic complication, to meeting diabetic's demand.
Health food of the present invention is mixed and forms with 5-15 weight portion zymophyte powder of caterpillar fungus through the concentrated extract powder of making of water extraction by 5～13 weight portion Radixs Astragali, 1～10 weight portion sealwort, 1-10 weight portion matrimony vine.
The raw materials used optimal proportion of the present invention is: zymophyte powder of caterpillar fungus 8-10 part weight portion, Radix Astragali 10-13 part weight portion, sealwort 5-10 weight portion, matrimony vine 5-10 weight portion.
Below provide a kind of preparation method of health food of the present invention:
(1) get zymophyte powder of caterpillar fungus 5-15 weight portions, the Radix Astragali 5～13 weight portions, sealwort weight 1～10 weight portion, matrimony vine weight 1-10 weight portion.
(2) step (1) Radix Astragali of getting, sealwort, matrimony vine are mixed, add 10 times of water of medicinal material weight, decoct 3 hours after immersion 2h, filter extract standby.
(3) dregs of a decoction that step (2) leached add 8 times of water of medicinal material dry weight again, decoct 2 hours, filter, and obtain extract.
(4) dregs of a decoction that step (3) leached add 6 times of water of medicinal material dry weight again, decoct 1 hour, filter, and obtain extract.
(5) step (2), (3), (4) gained extract are merged, staticly settle 24h, the centrifuging and taking supernatant.
(6) supernatant that will process through step (5) is at 60-70 ℃, steam pressure≤0.3Mpa, and vacuum >=0.05Mpa, concentrated extracting solution becomes the thick medicinal extract (temperature 60-70 ℃ mensuration) of density more than 1.30.
(7) dextrin that adds 3.5 times of weight ratios of thick medicinal extract in the thick medicinal extract of step (6) being processed, after drying is pulverized, cross 100 mesh sieves.
(8) extract powder of step (7) gained is jointly added in mixer and mixes with Chinese caterpillar fungus bacterium powder, but make the medicinal powder of the present invention's auxiliary hyperglycemic.
(9) medicinal powder of step (8) gained incapsulated or add other conventional pharmaceutical carrier or excipient to make the peroral dosage form of being convenient to take.
Foundation of the present invention is: Cordyceps sinensis is the entomogenous fungi association that Cordyceps Militaris and bat moth larvae form under the special ecological condition.In Chinese medicine, Cordyceps sinensis and ginseng, pilose antler are listed as China's three large tonics.Chinese medicine thinks, the Cordyceps sinensis nature and flavor are sweet, flat, enter the lung kidney channel, function benefit lung, kidney, controls cough, kidney tonifying damage, beneficial vital essence.Cordyceps sinensis has invigrating kidney, the effect of hemostasis and phlegm.In general Chinese caterpillar fungus, containing polysaccharide approximately 6%, cordycepic acid 7.8%, cordycepin 332mg/kg, separately containing several amino acids, alkaloid, sterol, organic acid etc.The research discovery, Cordyceps sinensis can have obvious activation to phagocytic activities such as mouse monokaryon phagocyte, peritoneal macrophage, reticuloendothelial systems; Can make immune organ thymus gland, spleen obviously increase weight; External handbag transformation is had to facilitation, can improve the content of serum IgG.Cordyceps sinensis has obvious adjusting immunity, by extensively cognitive and application.
Recent study is found, the first a kind of CHWG polysaccharide of separation and purification in winter worm summer herb thallus, and lumbar injection 50mg/kg, have obvious hypoglycemic activity, the 3h onset, 24h effect hour, have obvious hypoglycemic activity to the alloxan diabetes model mice.
In the present invention, select gather from Qinghai fresh to there is your green plum of bat moth that Cordyceps sinensis obtains from Hepialus larva body (bombys batryticatus) separation of doing, the cordyceps that the Paecilomyces hepiali chen submerged fermentation is obtained is primary raw material, this bacterium powder indices component content is stable, and its composition, effect are similar to the natural cs effect.Price is cheap than natural cs, conveniently is easy to get.Zymophyte powder of caterpillar fungus is monarch drug in a prescription in the present invention.
The dry root that the Radix Astragali is the pulse family Astragalus Radix Astragali, oval column type, pale yellow to lark, odorlessness, slightly sweet flavor, that chews has a beany flavor.Mainly be distributed in the areas such as China northeast, North China, northwest.Its main component be astragalus polyose, triterpene saponin, flavonoids and GABA etc. the materials such as plurality of inorganic salt such as 21 seed amino acids and selenium.
The water decoction of the Radix Astragali can improve the effects such as macrophage, T lymphocyte and the lymphocytic regulating power of β, and have the foot swelling of the egg white of reduction induced mice, reduction croton oil to cause the swollen effect of mouse ear, can improve leukocyte count, thymus index and the hypoxia-bearing capability of immunologic hypofunction mouse.
A few days ago, the Wuhan University Pathological Physiology is that the subject study of Ou Yangjingping professor and doctor Wu Yong etc. discloses first, and Chinese herbal medicine astragalus has the insulin sensitivity of increasing and falls hypoglycemic effect the diabetic.This project is by setting up four kinds of different animal models such as KKAy Mouse, oral administration or lumbar injection astragalus polyose, after treatment, body weight, blood sugar and insulin resistance index all reduce, can also improve IGT, slim the abdomen, increase insulin sensitivity, but do not affect insulin secretion.Research shows, Chinese herbal medicine astragalus can by increasing, glycogen synthetase be active, IRS is active, protein kinase b and Activity of Protein Kinase C, Skeletal Muscle Cell cardiac muscular tissue GLUT level is increased, make active the increasing of glycogen synthetase and increase insulin sensitivity, thereby performance reduces the blood sugar effect.In side, the Radix Astragali is ministerial drug.
Sealwort, have another name called tendrilleaf solomonseal rhizome, chicken head ginseng.Dry rhizome for liliaceous plant Yunnan sealwort (Polygonatum kingianum Coll.et Hemsl.), sealwort (Polygonatum sibiricum Red.) or David's-harp (Polygonatum cyrtonema Hua.).The property sweet, flat, return spleen; Lung; Kidney channel.There is boosting qi and nourishing yin, invigorating the spleen, moistening lung, kidney benefiting functions.Be used for the treatment of weakness of the spleen and the stomach, fatigue and asthenia, dry food is few, deficiency syndrome of the lung cough caused by dryness, asthenia of essence and blood, the interior heat disease such as quench one's thirst.Main product in Hebei, the provinces and regions such as Inner Mongol, Shaanxi Province.
Research is arranged by the Radix Astragali, sealwort, coptis compatibility, investigate its impact on alloxan diabetes rat insulin, blood sugar, serum total cholesterol and triglycerides, hemorheological property, MDA, SOD equal size, result shows, the Radix Astragali and sealwort compatibility have a better role to above-mentioned each observation index.The present invention, selecting sealwort is that assistant makes, and increases the effect of product auxiliary hyperglycemic.
Matrimony vine is the Solanaceae machaka, generally refers to its berry " fruit of Chinese wolfberry ", ovalize spindle shape, and dry finished product slightly is crushed.Orange red to kermesinus, distinguish the flavor of micro-sweet.Physiological activator in matrimony vine mainly contains three classes, is respectively to take carotenoid and be main pigment, can promote lipid-metabolism to there is the betaines of lipotropism liver protection effect, and a kind of nonspecific immunity strengthening agent---polysaccharide.
LBP-X can improve body's immunity, strengthens resistance against diseases, to reach anti-ageing, antitumor, anti-radioactive ray, the effect such as antiviral.LBP-X can be protected the NIT-L1 beta Cell of islet of Streptozotocin damage; the activity that suppresses alpha-glucosidase in alimentary canal; reduce the absorption of intestinal brush border to glucose, for suppressing the picked-up to glucose of glycogen generation and enhancing 3T3-L1 adipocyte, obvious effect is also arranged.In the present invention, LBP-X can strengthen immunity, but auxiliary hyperglycemic again is the medicine that makes in formula.
The invention has the beneficial effects as follows: for diabetes patient's characteristics, selecting zymophyte powder of caterpillar fungus, the Radix Astragali, sealwort, matrimony vine four traditional Chinese medicine material is raw material, by traditional traditional Chinese medical theory and modern medicine science, make its each component under certain conditions of mixture ratios, have and strengthen the difunctional of immunity and auxiliary hyperglycemic.The present invention of diabetic's long-term taking, when effectively controlling blood sugar, can improve the immunity of body, increases the especially ability of diabetic complication of body antagonism Other diseases.Selecting zymophyte powder of caterpillar fungus in side is raw material, and its chemical composition of this raw material, pharmacological action are basically identical in natural cs, have reduced production cost, alleviates and excessively carries out the environmental pollution caused because of natural cs.The present invention's preparation process routinely makes capsule, pulvis, granule etc., and it takes convenient.
Effect evaluation test of the present invention:
A, the health-caring capsule of the present invention animal function test to auxiliary hyperglycemic
1, materials and methods
1.1 sample: health-caring capsule of the present invention, content is light brown powder, recommended amounts is 5.4g/ day, i.e. 0.09g/kg BW, normal temperature is preserved.Open capsule and take out content for experiment.
1.2 animal used as test: 90 of the clean level of the health of selecting Jilin University's preclinical medicine section laboratory animal research center to provide Kunming mouses, credit number: SCXK (capital) 2010-0012.
1.3 dosage is selected to give mode with tested material: establish three dosage groups, 2.7g/kg BW (be equivalent to human body recommended amounts 3,10,30 times) respectively 0.27,0.90,, with distilled water, configure to desired concn, gavage amount 20mL/kg bw, establish the blank group simultaneously, control group gives the solvent of equal volume, continuous 30 days.
1.4 key instrument and reagent: animal weigh scale, steady bold and unconstrained type blood glucose meter.
1.5 experimental technique
1.5.1 reduce the fasting blood-glucose test
1.5.1.1 hyperglycemia model animal
After mouse fasting 24 hours, tail vein injection alloxan (45mg/kg.bw), after 5 days, fasting is 5 hours, surveys blood glucose value, and blood glucose value 10～25mmol/L is hyperglycemia model success animal.Select 40 of hyperglycemia model success animals, be divided into immediately a model control group and close three dosage groups (the poor 1.1mmol/L that is not more than between group).The dosage group gives variable concentrations and is subject to test solution, and model control group gives solvent, and continuous 30 days, fasting blood sugar, relatively each treated animal blood glucose value and blood sugar decline percentage were surveyed in fasting in 5 hours.
1.5.1.2 intact animal
20 mouse are by the grouping of the fasting blood sugar level of 5 hours, are divided into immediately 1 control group and 1 tested group, and tested group is subject to test solution, control group gives solvent, continuous 30 days, fasting blood sugar was surveyed in fasting in 5 hours, relatively each treated animal school value and blood sugar decline percentage.
Blood glucose value * 100% before blood sugar decline percentage=(blood glucose value after blood glucose value before experiment-test)/experiment.
1.5.2 carbohydrate tolerance test
Hyperglycemia model success animal fasting 5 hours, the dosage group gives variable concentrations and is subject to test solution, model control group gives same volume solvent, within 15-20 minute, by mouth, give glucose 2.0g/kg.bw, mensuration is the blood glucose value after 0,0.5,2 hour to glucose, observe model control group and given the test agent group to glucose after variation below each time point blood glucose curve.
Area under the curve of blood glucose=0.25 * (0 hours blood glucose value+4 * 0.5 hours blood glucose values+3 * 2 hours blood glucose values)
1.6 test data statistics: adopt the SPSS statistical software to carry out data analysis, each dosage group and model control group relatively adopt variance analysis, with the comparative approach in twos of a plurality of experimental group and a control group mean, added up: the data of heterogeneity of variance are carried out to suitable variable conversion, after meeting the neat requirement of variance, by the data after transforming, added up, model control group and blank group relatively adopt the t check.
1.7 result is judged: an index positive in fasting blood-glucose and sugar tolerance binomial index, and on the intact animal fasting blood-glucose without impact, can judge this tested material sample auxiliary hyperglycemic function experimental result positive.
2, result
2.1 the impact of the present invention on the weight of animals
By the visible high dose of table 1 to normal mouse, each dosage to each time point body weight of hyperglycemia model mouse without conspicuousness (P>0.05)
The impact (X ± s, g) of table 1 the present invention on normal Mouse Weight
The impact (X ± s, g) of table 1-2 the present invention on the hyperglycemia model Mouse Weight
2.2 the impact of the present invention on the normal mouse fasting blood-glucose
In Table 2, give the product 30 days of mouse high dose through button, to the intact animal fasting blood sugar, blood sugar decline percentage has no significant effect (P>0.05).
The impact (X ± s) of table 2 the present invention on the normal mouse fasting blood-glucose
2.3 the impact of the present invention on hyperglycemia model animal fasting blood-glucose
From table 3, per os gives the product 30 days of mouse various dose, and each dosage group mouse fasting blood-glucose measured value and control group are relatively without explicitly difference (P>0.05).Each dosage group mouse blood sugar decline percentage and control group relatively have the trend of increasing, and relatively, difference has conspicuousness (P<0.05) for high dose group and control group.
The impact (X ± s) of table 3 the present invention on hyperglycemia model animal fasting blood-glucose
2.4 the impact of product on hyperglycemia model animal sugar tolerance
In Table 4, per os gives the sample 30 days of mouse various dose, and each dosage group mouse blood sugar TG-AUC and control group be there was no significant difference (P>0.05) relatively.
The impact (X ± s) of table 4 sample on hyperglycemia model animal sugar tolerance
3, conclusion
Under this laboratory condition; per os gives this product 30 days of mouse 0.27g/kg.bw, 0.90g/kg.bw, 2.7g/kg.bw dosage; high dose group hyperglycemia model mouse blood sugar decline percentage and control group relatively have and increase; difference has conspicuousness, and hyperglycemia model mouse fasting blood-glucose measured value, Area under the curve of blood glucose are had no significant effect to (P>0.05); The normal mouse fasting blood-glucose is had no significant effect to (P>0.05).Prompting, this sample has auxiliary hyperglycemic function to animal.
B, health-care powder of the present invention strengthen the animal function test of immunity
1, materials and methods
1.1 sample: powder of the present invention, light brown powder, recommended amounts is 5.4g/ day, i.e. 0.09g/kg BW, normal temperature is preserved.
1.2 animal used as test: 80 of the clean level of the health of selecting Jilin University's preclinical medicine section laboratory animal research center to provide Kunming mouses, credit number: SCXK (capital) 2010-0012.
1.3 experimental animal room environmental condition: 22～25 ℃ of zoopery room temperatures, relative humidity 55～75%.
1.4 dosage is selected to give mode with tested material: establish three dosage groups, 1.8g/kg BW (be equivalent to human body recommended amounts 5,10,20 times) respectively 0.45,0.90,, with distilled water, configure to desired concn, gavage amount 20mL/kg bw, establish the blank group simultaneously, control group gives the solvent of equal volume, continuous 30 days.
1.5 key instrument and reagent: animal weigh scale, electronic molecules balance, centrifuge, clean bench, CO2gas incubator, constant water bath box, microscope, semi-automatic biochemical analyzer, gland mark instrument etc.
1.6 experimental technique
1.6.1 internal organs/weight ratio pH-value determination pH: the rear execution mouse of weighing, take out Thymus and spleen, on electronic analytical balance, weigh, calculate dirty/body ratio.
1.6.2ConA the mouse spleen lymphocyte conversion test of inducing
The aseptic spleen of getting, be placed in the plate that fills appropriate aseptic Hank ' s liquid, make cell suspension, through 200 eye mesh screens, filter, use Hank ' s liquid to wash 2 times, each centrifugal 10min (1000r/min), then be suspended in cell in the 1mL complete culture solution, the living cell counting number, adjusting cell concentration with the RPM1640 nutrient solution is 3 * 10
6individual/mL.Again cell suspension is divided two holes to add in 24 well culture plates, every hole 1mL, wherein a hole adds 75 μ LConA liquid (being equivalent to 7.5 μ g/mL), and 5%CO in contrast, is put in another hole
2cultivate 72h in 37 ℃ of titanium dioxide incubators,
Cultivate and finish front 4h, every hole sucks supernatant 0.7mL gently, adds 0.7mL containing the RPMI1640 nutrient solution of calf serum, adds MTT (5mg/mL) 50 μ L/ holes simultaneously.Continue to cultivate 4h.After cultivating end, every hole adds 1mL acid isopropyl alcohol, and piping and druming mixes, and purple crystal is dissolved fully.Then divide and install in 96 well culture plates, 3 parallel holes are made in each hole, use ELIASA, with the 570nm wavelength, measure OD value.The OD value that lymphocytic competence for added value pressure adds the ConA hole deducts the OD value that does not add the ConA hole and means.
1.6.3 the mensuration of serum hemolysin (Hemagglutination Method)
Get the sheep blood of holder fiber, with physiological saline washing 3 times, each centrifugal 10min(2000r/min), with physiological saline, hematocrit SRBC is made into to 2% cell suspension, every mouse abdominal cavity registration 0.2mL.After immunity 5 days, extract the eyeball of mouse, get blood in centrifuge tube, place about 1h, the centrifugal 10min of 2000r/min.Separate mobile phone serum.With physiological saline by the serum doubling dilution, the dilution serum of difference is placed in respectively in the Microhemagglutination version, every hole 100 μ L, the SRBC suspension that adds again 100 μ L0.5%, mix, add a cover in the moistening square position of packing into, in 37 ℃ of incubation 3H, observe the hemagglutination degree, be calculated as follows the antibody product:
Antibody product=(S
1+ 2S
2+ 3S
3+ ... + nS
n)
In formula 1,2,3 ... the index that n is the two-fold dilution, the rank that S is the aggegation degree.
1.7 test data statistics: adopt the SPSS statistical software to carry out data analysis, each dosage group and model control group relatively adopt variance analysis, with the comparative approach in twos of a plurality of experimental group and a control group mean, added up: the data of heterogeneity of variance are carried out to suitable variable conversion, after meeting the neat requirement of variance, by the data after transforming, added up, model control group and blank group relatively adopt the t check.
1.8 result is judged: an index positive in cellular immune function and NK cytoactive binomial index, and immune organ internal organs/body weight ratio is had no significant effect, can judge that this tested material sample has the immunity function of the enhancing experimental result positive.
2, result
2.1 the impact of the present invention on Mouse Weight
Initial, mid-term, final period and weightening finish and control group comparison, difference that there are no significant (P>0.05) by visible each dosage group mouse of table 1.
The impact (X ± s, g) of table 1 the present invention on normal Mouse Weight
2.2 the impact of the present invention on mouse immune organ internal organs/body weight ratio
Given the product 30 days of mouse various dose by the visible per os of table 2, the thymus gland of mouse/batheroom scale spleen/body weight ratio and negative control group comparison, difference that there are no significant (P>0.05).
The impact (X ± s, g) of table 2 the present invention on normal Mouse Weight
2.3 the impact of the present invention on the cellular immunity of mouse
In Table 3, per os gives the product 30 days of mouse various dose, the SPL conversion capability of each dosage group is all higher than negative control group, but the difference of each dosage group and negative control group, all without significant difference, shows that this sample promoted used yesterday to spleen lymphocyte proliferation, the conversion capability of mouse without obvious.
The impact (X ± s) of table 3 the present invention on the mouse cell immunity
2.4 the impact of the present invention on mice serum haemolysis number
From table 4, per os gives the product 30 days of mouse various dose, and each dosage group antibody product is all higher than control group, and the difference of high dose group and negative control group has conspicuousness (P<0.05).
The impact (X ± s) of table 4 the present invention on mice serum haemolysis number
3, conclusion
Under this laboratory condition; per os gives this product 30 days of mouse 0.45g/kg.bw, 0.90g/kg.bw, 1.8g/kg.bw dosage; in low, a Senior Three dosage group all can improve the serum hemolysin of mouse; wherein high dose group has conspicuousness to the serum hemolysin that improves mouse, and the mouse spleen lymphocyte conversion capability that ConA is induced has no significant effect (P>0.05); Mouse Weight weightening finish, immune organ internal organs/body weight ratio are had no significant effect to (P>0.05).Prompting, this sample has the enhancing immunity function to animal.
The specific embodiment
1, get by weight proportion 10 parts of zymophyte powder of caterpillar fungus, 13 parts of the Radixs Astragali, 8 parts of sealworts, 5 parts of matrimony vines
2, the Radix Astragali that step 1 is got, sealwort, matrimony vine are mixed, by 10 times of water of medicinal material weight, decoct 3 hours after immersion 2h, filter extract standby.
3, the dregs of a decoction that step 2 leached add 8 times of water of medicinal material dry weight again, decoct 2 hours, filter, and obtain extract.
4, the dregs of a decoction that step 3 leached add 6 times of water of medicinal material dry weight again, decoct 1 hour, filter, and obtain extract.
5, step 2,3,4 gained extracts are merged, staticly settle 24h, the centrifuging and taking supernatant.
6, the supernatant that will process through step 5 is at 60-70 ℃, steam pressure≤0.3Mpa, and vacuum >=0.05Mpa, concentrated extracting solution becomes the thick medicinal extract (temperature 60-70 ℃ mensuration) of density more than 1.30.
7, the dextrin that adds 3.5 times of weight ratios of thick medicinal extract in the thick medicinal extract of step 6 being processed, after drying is pulverized, cross 100 mesh sieves.
8, the extract powder of step 7 gained is jointly added in mixer and mixes with Chinese caterpillar fungus bacterium powder, make medicinal powder of the present invention.
9, the medicinal powder of step 8 gained is incapsulated, obtain.
Claims (4)
1. one kind has the health food that strengthens immunity and auxiliary hyperglycemic function, it is characterized in that: active component is comprised of with 5 ~ 13 parts of the Radixs Astragali, 1 ~ 10 part of sealwort, matrimony vine 1-10 part water extraction or gained extract powder 5-15 parts of zymophyte powder of caterpillar fungus.
2. a kind of health food that strengthens immunity and auxiliary hyperglycemic function that has according to claim 1, is characterized by zymophyte powder of caterpillar fungus 8-10 part weight portion, Radix Astragali 10-13 part weight portion, sealwort 5-10 weight portion, matrimony vine 5-10 weight portion.
3. the preparation method with the health food that strengthens immunity and auxiliary lipid-lowering function who requires as right 1, comprise the steps:
(1) get zymophyte powder of caterpillar fungus 5-15 weight portions, the Radix Astragali 5 ~ 13 weight portions, sealwort weight 1 ~ 10 weight portion, matrimony vine weight 1-10 weight portion;
(2) step (1) Radix Astragali of getting, sealwort, matrimony vine are mixed, add 10 times of water of medicinal material weight, decoct 3 hours after immersion 2h, filter extract standby;
(3) dregs of a decoction that step (2) leached add 8 times of water of medicinal material dry weight again, decoct 2 hours, filter, and obtain extract;
(4) dregs of a decoction that step (3) leached add 6 times of water of medicinal material dry weight again, decoct 1 hour, filter, and obtain extract;
(5) step (2), (3), (4) gained extract are merged, staticly settle 24h, the centrifuging and taking supernatant;
(6) supernatant that will process through step (5) is at 60-70 ℃, steam pressure≤0.3Mpa, vacuum >=0.05Mpa, the thick medicinal extract of density more than 1.30 when concentrated extracting solution becomes temperature 60-70 ℃;
(7) dextrin that adds 3.5 times of weight ratios of thick medicinal extract in the thick medicinal extract of step (6) being processed, after drying is pulverized, cross 100 mesh sieves;
(8) extract powder of step (7) gained is jointly added in mixer and mixes with Chinese caterpillar fungus bacterium powder;
(9) step (8) gained mixture incapsulated or add other conventional pharmaceutical carrier or excipient to make the peroral dosage form of being convenient to take, must there is the health food that strengthens immunity and auxiliary hyperglycemic function.
4. a kind of preparation method who strengthens immunity and the bifunctional health food of auxiliary hyperglycemic that has according to claim 3, it is characterized in that: made peroral dosage form is capsule, powder, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310466624.8A CN103494197A (en) | 2013-10-09 | 2013-10-09 | Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310466624.8A CN103494197A (en) | 2013-10-09 | 2013-10-09 | Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103494197A true CN103494197A (en) | 2014-01-08 |
Family
ID=49859536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310466624.8A Pending CN103494197A (en) | 2013-10-09 | 2013-10-09 | Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494197A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103976360A (en) * | 2014-05-23 | 2014-08-13 | 北京三奇本草科技有限公司 | Health food with thirsty quenching function |
| CN105560838A (en) * | 2016-01-29 | 2016-05-11 | 杭州鑫伟低碳技术研发有限公司 | Haematococcus pluvialis astaxanthin for adjuvant treatment of diabetes and preparation method thereof |
| CN106880045A (en) * | 2015-12-15 | 2017-06-23 | 东莞市永益食品有限公司 | Application of the honey matrimony vine tomato juice in strengthen immunity health food is prepared |
| CN106943517A (en) * | 2016-01-06 | 2017-07-14 | 吉林大清鹿苑保健科技有限公司 | A kind of health products of strengthen immunity and preparation method thereof |
| CN107212376A (en) * | 2017-06-30 | 2017-09-29 | 湖北思慧生物科技有限公司 | It is a kind of that there is hypoglycemic, reducing blood lipid, strengthen immunity, the composition of anti-oxidation efficacy, beverage and its application |
| CN107279419A (en) * | 2017-06-30 | 2017-10-24 | 湖北思慧生物科技有限公司 | It is a kind of that there is hypoglycemic, reducing blood lipid, strengthen immunity, pressed candy of anti-oxidation efficacy and its preparation method and application |
| CN108936654A (en) * | 2018-06-12 | 2018-12-07 | 北京筑元吉康医药科技有限责任公司 | A kind of health food of strengthen immunity and its application |
| CN112245527A (en) * | 2020-11-11 | 2021-01-22 | 广东轻工职业技术学院 | Preparation method of active polysaccharide extract, functional beverage and effervescent granule with homology of medicine and food |
| CN114271494A (en) * | 2021-12-30 | 2022-04-05 | 杨环宇 | Beverage for improving kidney function and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1393262A (en) * | 2001-07-02 | 2003-01-29 | 福州金大生物工程技术开发有限公司 | Process for preparing nutritive health-care oral liquid |
| CN1509760A (en) * | 2002-12-25 | 2004-07-07 | 广东东方神草药业有限公司 | Medicine for preventing and auxiliary treating cancer |
| CN1586300A (en) * | 2004-06-28 | 2005-03-02 | 陈萍 | Method for preparing health food for improving immunological function |
| WO2005030231A1 (en) * | 2003-09-28 | 2005-04-07 | Shaosheng Sun | The extractive of aweto and process for its preparation and uses |
| CN102293430A (en) * | 2011-06-24 | 2011-12-28 | 于光远 | Beverage with functions of antioxidation and immunity enhancing, and preparation method thereof |
| CN102526477A (en) * | 2010-12-28 | 2012-07-04 | 北京润康普瑞生物技术有限公司 | Medicine composition for enhancing immunities as well as preparation method and application thereof |
| CN103005445A (en) * | 2012-12-22 | 2013-04-03 | 北华大学 | Compound healthcare product capable of improving immunity |
-
2013
- 2013-10-09 CN CN201310466624.8A patent/CN103494197A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1393262A (en) * | 2001-07-02 | 2003-01-29 | 福州金大生物工程技术开发有限公司 | Process for preparing nutritive health-care oral liquid |
| CN1509760A (en) * | 2002-12-25 | 2004-07-07 | 广东东方神草药业有限公司 | Medicine for preventing and auxiliary treating cancer |
| WO2005030231A1 (en) * | 2003-09-28 | 2005-04-07 | Shaosheng Sun | The extractive of aweto and process for its preparation and uses |
| CN1586300A (en) * | 2004-06-28 | 2005-03-02 | 陈萍 | Method for preparing health food for improving immunological function |
| CN102526477A (en) * | 2010-12-28 | 2012-07-04 | 北京润康普瑞生物技术有限公司 | Medicine composition for enhancing immunities as well as preparation method and application thereof |
| CN102293430A (en) * | 2011-06-24 | 2011-12-28 | 于光远 | Beverage with functions of antioxidation and immunity enhancing, and preparation method thereof |
| CN103005445A (en) * | 2012-12-22 | 2013-04-03 | 北华大学 | Compound healthcare product capable of improving immunity |
Non-Patent Citations (1)
| Title |
|---|
| 王宫，等: "安心胶囊对小鼠抗疲劳及心功能影响的实验研究", 《福建中医学院学报》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103976360A (en) * | 2014-05-23 | 2014-08-13 | 北京三奇本草科技有限公司 | Health food with thirsty quenching function |
| CN103976360B (en) * | 2014-05-23 | 2016-03-16 | 北京三奇本草科技有限公司 | A kind of health food with the effect of quenching one's thirst |
| CN106880045A (en) * | 2015-12-15 | 2017-06-23 | 东莞市永益食品有限公司 | Application of the honey matrimony vine tomato juice in strengthen immunity health food is prepared |
| CN106943517A (en) * | 2016-01-06 | 2017-07-14 | 吉林大清鹿苑保健科技有限公司 | A kind of health products of strengthen immunity and preparation method thereof |
| CN105560838A (en) * | 2016-01-29 | 2016-05-11 | 杭州鑫伟低碳技术研发有限公司 | Haematococcus pluvialis astaxanthin for adjuvant treatment of diabetes and preparation method thereof |
| CN107212376A (en) * | 2017-06-30 | 2017-09-29 | 湖北思慧生物科技有限公司 | It is a kind of that there is hypoglycemic, reducing blood lipid, strengthen immunity, the composition of anti-oxidation efficacy, beverage and its application |
| CN107279419A (en) * | 2017-06-30 | 2017-10-24 | 湖北思慧生物科技有限公司 | It is a kind of that there is hypoglycemic, reducing blood lipid, strengthen immunity, pressed candy of anti-oxidation efficacy and its preparation method and application |
| CN108936654A (en) * | 2018-06-12 | 2018-12-07 | 北京筑元吉康医药科技有限责任公司 | A kind of health food of strengthen immunity and its application |
| CN112245527A (en) * | 2020-11-11 | 2021-01-22 | 广东轻工职业技术学院 | Preparation method of active polysaccharide extract, functional beverage and effervescent granule with homology of medicine and food |
| CN114271494A (en) * | 2021-12-30 | 2022-04-05 | 杨环宇 | Beverage for improving kidney function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494197A (en) | Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food | |
| CN103800390B (en) | Health-care product with immunity-reinforcing and liver-protecting functions, preparation method and application thereof | |
| CN103285231A (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN102526477B (en) | Medicine composition for enhancing immunities as well as preparation method and application thereof | |
| CN101856120A (en) | Health food for improving immunity of human body and preparation method thereof | |
| CN104187678B (en) | A kind of health composition of reducing blood lipid and production method thereof | |
| CN103585400A (en) | Composition having immunity enhancing and fatigue alleviating effects, and preparation method thereof | |
| CN103155985B (en) | Rhizoma polygonati nutrition powder and preparation method thereof | |
| CN104857334A (en) | Hypoglycemic wine and preparation method thereof | |
| CN103816278A (en) | Composition for reducing blood sugar and application thereof | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN103445176B (en) | Develop immunitypty health food and preparation method thereof | |
| CN106728387B (en) | Compound medicine with function of promoting immunity and preparation method thereof | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN105055851B (en) | A kind of Chinese medicine composition that treating diabetes, its preparation and its application | |
| CN108165499A (en) | A kind of culture medium of Hericium erinaceus, Chinese yam bioconversion mycelium, the mycelial extract of Chinese yam bioconversion and application thereof | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN103230003B (en) | Health food with immunity boosting function and preparation method thereof | |
| CN106421741A (en) | Water-soluble olive leaf extract health-care product and preparation method thereof | |
| CN101129604B (en) | Antihypelipidemic traditional Chinese medicine producing method | |
| CN107802695A (en) | A kind of health composition of the strengthen immunity containing saline cistanche and preparation method thereof | |
| CN105998196A (en) | Blood sugar decreasing healthcare pharmaceutical composition prepared from fiveleaf gynostemma herb | |
| CN105815786A (en) | Tablets prepared from honeysuckle flowers, wild chrysanthemum flowers and rhizoma polygonati and preparation method of tablets | |
| CN106177176B (en) | A kind of Halth-care composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140108 |